Want to see NXGL full AI Analyst Report?
NXGL Stock Chart & Stats
$1.64
-$0.06(-1.71%)
At close: 4:00 PM EST
$1.64
-$0.06(-1.71%)
Day’s Range― - ―
52-Week Range$0.42 - $2.89
Previous CloseN/A
Volume27.00K
Average Volume (3M)50.95K
Market Cap
$5.57M
Enterprise Value$7.85
Total Cash (Recent Filing)$208.00K
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding9,225,242
10 Day Avg. Volume60,354
30 Day Avg. Volume50,949
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.84
Price to Sales (P/S)1.11
P/FCF Ratio-9.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)$24.06M
Bulls Say, Bears Say
Bulls Say
Expanded Commercial Footprint Via BioNX AcquisitionBuying BioNX provides an established commercial product set and reimbursement pathways, creating a durable revenue base across healthcare customers. The deal immediately expands distribution and product mix, increasing scale potential and reducing reliance on legacy consumer lines over the medium term.
Strategic Financing And Partner Support (Sequence LifeScience)Sequence’s capital, manufacturing role and board seats align financing, production and distribution capabilities with NexGel’s growth plan. That partnership materially strengthens execution capacity and access to customers, lowering integration and commercialization risk versus an unaffiliated investor.
Improving Product Gross MarginsA near-40% gross margin indicates stronger product economics from hydrogel and regenerative offerings; sustained margins give room to absorb SG&A and support profitability as sales scale, making long-term margin sustainability a credible path if volume growth continues.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow means the company cannot self-fund growth and must rely on external financing. That structural cash burn elevates dilution and refinancing risk and pressures timing of integration investments and commercialization over the coming months.
Rising Leverage Reduces FlexibilityDebt roughly matching equity after recent financings increases fixed obligations and limits balance-sheet flexibility. Higher leverage constrains strategic options and raises the breakeven threshold for new product lines, making execution-dependent growth riskier if margins or volumes disappoint.
Step-up In SG&A And Integration CostsA recurring ~$500k monthly incremental run-rate for sales, R&D and commissions materially raises the company’s fixed cost base. This structural cost step-up requires sustained, higher revenue to reach accretion and increases execution risk during integration and commercialization phases.
NexGel Inc News
NXGL FAQ
What was NexGel Inc’s price range in the past 12 months?
NexGel Inc lowest stock price was $0.42 and its highest was $2.89 in the past 12 months.
What is NexGel Inc’s market cap?
NexGel Inc’s market cap is $5.57M.
When is NexGel Inc’s upcoming earnings report date?
NexGel Inc’s upcoming earnings report date is Aug 18, 2026 which is in 27 days.
How were NexGel Inc’s earnings last quarter?
Currently, no data Available
Is NexGel Inc overvalued?
According to Wall Street analysts NexGel Inc’s price is currently Undervalued.
Does NexGel Inc pay dividends?
NexGel Inc does not currently pay dividends.
What is NexGel Inc’s EPS estimate?
NexGel Inc’s EPS estimate is -0.12.
How many shares outstanding does NexGel Inc have?
NexGel Inc has 9,225,242 shares outstanding.
What happened to NexGel Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NexGel Inc?
Currently, no hedge funds are holding shares in NXGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NexGel Inc
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
NXGL Stock 12 Month Forecast
Average Price Target
$2.00
▲(21.95% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
Sanara MedTech
―
Femasys
―
Ownership Overview
4.73% Insiders
1.13% Mutual Funds
0.95% Other Institutional Investors
92.66% Public Companies and
Individual Investors